Alan S. Cross

Potential hazards of combination immunotherapy in the treatment of experimental septic shock.

S. Opal, A. Cross, J. Jhung, 1996, The Journal of infectious diseases.

Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.

S. Opal, S. Opal, A. Cross, 1990, The Journal of infectious diseases.

Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection.

D. Hoover, A. Cross, A. Neely, 1996, Burns : journal of the International Society for Burn Injuries.

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

A. Cross, S. Cryz, J. Sadoff, 1987, The Journal of clinical investigation.

Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli.

A. Cross, J. Sadoff, P. Gemski, 1986, The Journal of infectious diseases.

The importance of the K1 capsule in invasive infections caused by Escherichia coli.

A. Cross, J. Sadoff, P. Gemski, 1984, The Journal of infectious diseases.

Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans.

A. Cross, J. Sadoff, B. Iglewski, 1980, The Journal of infectious diseases.

Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC.

A. Cross, J. Sadoff, R. Warren, 1996, The Journal of infectious diseases.

Inflammatory cytokines produced in response to experimental human gonorrhea.

A. Cross, D. Hoover, R. Kuschner, 1995, The Journal of infectious diseases.